Project 1
Project 1
批准号:
10229390
负责人:
Stanley Perlman
金额:
$8.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-07-01 至 2023-07-31
关键词:
AffectAgeAge-YearsAgingAlveolar MacrophagesAnimalsAnti-Inflammatory AgentsAntigensCase Fatality RatesCell CommunicationCellsCellular MembraneChronicCollaborationsCoronavirus InfectionsDendritic CellsDendritic cell activationDependenceDepressed moodDinoprostoneDiseaseDopamine D2 ReceptorEicosanoidsElderlyExposure toFundingGeneticGoalsHumanITGAX geneImmune responseIndividualInfectionInflammasomeInflammationInflammatoryInterferonsKnock-in MouseLungLung diseasesMiddle East Respiratory SyndromeMiddle East Respiratory Syndrome CoronavirusMusMyeloid CellsOutcomeOxidative Stress InductionPathogenicityPathway interactionsPatientsPeripheral Blood Mononuclear CellPhospholipasePhospholipase A2PropertyProstaglandin D2ProstaglandinsRespiratory Tract InfectionsRoleSARS coronavirusSevere Acute Respiratory SyndromeSeverity of illnessSignal TransductionSystemT cell responseTimeUp-RegulationVaccinesViralVirulentVirusage relatedagedaging populationcell motilitydraining lymph nodeinflammatory milieulipid mediatormacrophagemembermiddle agemortalitypathogenreceptorrespiratoryrespiratory pathogenresponsevaccine developmentvaccine responsevaccine trialvirology
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS) are
coronavirus-induced human respiratory diseases with high case-fatality rates. Disease is especially
severe in aged populations. In the previous funding period, we showed that age-dependent increases
in prostaglandin D2 (PGD2) and an upstream phospholipase A2, PLA2G2D contributed to poor
immune responses and decreased survival. The lung is in a state of chronic inflammation, resulting
from continued exposure to environmental antigens. We postulated that PLA2G2D, which has anti-
inflammatory properties, is upregulated to counter this low grade inflammation, resulting in delayed
responses to innocuous antigens but also to rapidly replicating viruses like MERS-CoV and SARS-
CoV. In contrast, genetic absence of DP1, the PGD2 receptor on myeloid cells, appears to result in
poor respiratory dendritic cell activation suggesting that PGD2-DP1 signaling may have pro-
inflammatory properties at early times after infection. Our central hypothesis is that small lipid
mediators are major factors in the inflammatory milieu in the lung, affecting many aspects of the
immune response to MERS-CoV, SARS-CoV and other respiratory pathogens. This hypothesis will be
approached in the following specific aims: 1. To determine the mechanism of PLA2G2D upregulation
and the role of PLA2G2D in vaccine responses in 12m old mice. CoV replication includes extensive
cellular membrane rearrangements. The role between these rearrangements, the induction of oxidative
stress and the upregulation of PLA2G2D will be investigated. 2. To determine the role of PGD2-DP1
signaling in the immune response to SARS-CoV in 12 m mice. The absence of PGD2-DP1 signaling
results in diminished rDC activation and type I IFN (IFN-I) expression and increased inflammasome
activation. Our goal is to determine whether changes in inflammasome activation are the major
pathogenic effect of absent PGD2-DP1 signaling or if other factors are also involved. 3. To determine
whether disease severity in murine MERS is age-dependent and whether PGD2 and PLA2G2D
contribute to poorer outcomes. Using our newly developed hDPP4-KI mice and mouse-adapted
MERS-CoV, we will determine whether MERS-CoV in mice also causes an age-dependent disease.
We will also assess whether changes in eicosanoid expression contribute to more severe disease.
MERS-CoV, unlike SARS-CoV, productively infects macrophages. In this aim we will determine
whether productive infection of human and murine macrophages modulates PLA2G2D expression.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Role of eicosanoids in pathogenic human CoV infections
-
批准号:9764251
-
项目类别:
-
资助金额:$54.52万
-
财政年份:2016
-
负责人:Stanley Perlman
-
依托单位:
Role of eicosanoids in pathogenic human CoV infections
-
批准号:9542722
-
项目类别:
-
资助金额:$54.52万
-
财政年份:2016
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8847630
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Animal Core
-
批准号:8055144
-
项目类别:
-
资助金额:$22.62万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8164278
-
项目类别:
-
资助金额:$37.73万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8055138
-
项目类别:
-
资助金额:$31.54万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8264955
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Administrative Core
-
批准号:8055145
-
项目类别:
-
资助金额:$13.24万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8468102
-
项目类别:
-
资助金额:$35.49万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
Role of anti-SARS-CoV T cell response in pathogenesis
-
批准号:8663180
-
项目类别:
-
资助金额:$37.75万
-
财政年份:2011
-
负责人:Stanley Perlman
-
依托单位:
A novel strategy for developing a SARS-CoV vaccine
-
批准号:7904591
-
项目类别:
-
资助金额:$40.33万
-
财政年份:2009
-
负责人:Stanley Perlman
-
依托单位:
PPG: HOST VIRUS INTERACTIONS IN HCoV-SARS INFECTIONS
-
批准号:7120540
-
项目类别:
-
资助金额:$144.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8021280
-
项目类别:
-
资助金额:$159.97万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8304203
-
项目类别:
-
资助金额:$159.58万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8881046
-
项目类别:
-
资助金额:$159.58万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:9752412
-
项目类别:
-
资助金额:$125.43万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
PPG: SARS-CoV-host cell interactions and vaccine development
-
批准号:8494515
-
项目类别:
-
资助金额:$160.57万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Project 4
-
批准号:9209901
-
项目类别:
-
资助金额:$19.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Development of Murine Model for SARS-CoV Pathogenesis
-
批准号:6825517
-
项目类别:
-
资助金额:$28.54万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
Project-004
-
批准号:10229091
-
项目类别:
-
资助金额:$18.24万
-
财政年份:2004
-
负责人:Stanley Perlman
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: